Literature DB >> 21696233

Investigations with spectroscopy, zeta potential and molecular modeling of the non-cooperative behaviour between cyclophosphamide hydrochloride and aspirin upon interaction with human serum albumin: binary and ternary systems from multi-drug therapy.

Zahra Omidvar1, Kazem Parivar, Hamideh Sanee, Zeinab Amiri-Tehranizadeh, Ali Baratian, Mohammad Reza Saberi, Ahmad Asoodeh, Jamshidkhan Chamani.   

Abstract

The interaction between cyclophosphamide hydrochloride (CYC) and aspirin (ASA) with human serum albumin (HSA) was studied by various kind of spectroscopic, ζ potential and molecular modeling under physiological conditions. The fluorescence data showed that the binding of drugs to proteins caused strong static fluorescence quenching. The analysis of the fluorescence quenching of HSA in the binary and ternary systems displayed that ASA was affected by the complex formed between CYC and HSA. Moreover, CYC was influenced by the HSA-ASA complex. The inherent binding information, including the quenching mechanism, binding constants, number of binding sites, effective quenching constant, fraction of the initial fluorescence and thermodynamic parameters were measured by the fluorescence quenching technique at various temperatures. In addition, according to the synchronous fluorescence spectra of HSA, the results showed that the fluorescence quenching of HSA originated from the Trp and Tyr residues, and indicated a conformational change of HSA with the addition of the drugs. Far-UV CD spectra of HSA were recorded before and after the addition of ASA and CYC as binary and ternary systems. An increase in intensity of the positive CD peak of HSA was observed in the presence of the drugs. The results were interpreted by excited interactions between the aromatic residues of the HSA binding sites and the drugs bound to them. The distance r between donor and acceptor was obtained by the Forster energy according to fluorescence resonance energy transfer (FRET) and found to be 2.35 nm and 1.78 nm for CYC and ASA, respectively. This confirmed the existence of static quenching for proteins in the presence of CYC and ASA. Furthermore, docking studies pointed at a reduction of the affinity of each of the drug compounds to the protein in the presence of the other in meaningful amounts. Pre-binding of any of the said compounds forced the second to bind in a non-optimized location and orientation. The potential at the electrokinetic shear surface of the protein-drug solution were measured at several concentrations of the drugs by the ζ potential technique, which confirmed experimental and theoretical results.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21696233     DOI: 10.1080/07391102.2011.10507382

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  10 in total

1.  Investigation of the Interaction Between Human Serum Albumin and Two Drugs as Binary and Ternary Systems.

Authors:  Nooshin Abdollahpour; Vahid Soheili; Mohammad Reza Saberi; Jamshidkhan Chamani
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

2.  Theoretical models for electrochemical impedance spectroscopy and local ζ-potential of unfolded proteins in nanopores.

Authors:  Michael J Vitarelli; David S Talaga
Journal:  J Chem Phys       Date:  2013-09-14       Impact factor: 3.488

3.  Insight on the microscopic binding mechanism of bisphenol compounds (BPs) with transthyretin (TTR) based on multi-spectroscopic methods and computational simulations.

Authors:  Muwei Huang; Xiaomei Huang; Li Yong; Dan Jia; Wangli Miao; Hongyan Liu; Zhongsheng Yi
Journal:  Anal Bioanal Chem       Date:  2022-04-08       Impact factor: 4.142

4.  Identification of cow and buffalo milk based on Beta carotene and vitamin-A concentration using fluorescence spectroscopy.

Authors:  Rahat Ullah; Saranjam Khan; Hina Ali; Muhammad Bilal; Muhammad Saleem
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

5.  Warfarin and Flavonoids Do Not Share the Same Binding Region in Binding to the IIA Subdomain of Human Serum Albumin.

Authors:  Hrvoje Rimac; Claire Dufour; Željko Debeljak; Branka Zorc; Mirza Bojić
Journal:  Molecules       Date:  2017-07-11       Impact factor: 4.411

6.  Probing the interaction of human serum albumin with norfloxacin in the presence of high-frequency electromagnetic fields: fluorescence spectroscopy and circular dichroism investigations.

Authors:  Olga Azimi; Zahra Emami; Hanieh Salari; Jamshidkhan Chamani
Journal:  Molecules       Date:  2011-11-25       Impact factor: 4.411

7.  Synthesis of novel coumarin nucleus-based DPA drug-like molecular entity: In vitro DNA/Cu(II) binding, DNA cleavage and pro-oxidant mechanism for anticancer action.

Authors:  Saman Khan; Ali Mohammed Malla; Atif Zafar; Imrana Naseem
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

8.  A resonance Rayleigh scattering sensor for sensitive differentiation of telomere DNA length and monitoring special motifs (G-quadruplex and i-motif) based on the Ag nanoclusters and NAND logic gate responding to chemical input signals.

Authors:  Shuai Wang; Fei Qu; Wenli Han; Jinmao You
Journal:  J Nanobiotechnology       Date:  2018-10-09       Impact factor: 10.435

9.  Investigation on the interaction between cyclophosphamide and lysozyme in the presence of three different kind of cyclodextrins: determination of the binding mechanism by spectroscopic and molecular modeling techniques.

Authors:  Mahdieh Mansouri; Malihe Pirouzi; Mohammad Reza Saberi; Maryam Ghaderabad; Jamshidkhan Chamani
Journal:  Molecules       Date:  2013-01-11       Impact factor: 4.411

10.  Synthesis, Structural, and Cytotoxic Properties of New Water-Soluble Copper(II) Complexes based on 2,9-Dimethyl-1,10-Phenanthroline and Their One Derivative Containing 1,3,5-Triaza-7-Phosphaadamantane-7-Oxide.

Authors:  Ewelina I Śliwa; Urszula Śliwińska-Hill; Barbara Bażanów; Miłosz Siczek; Julia Kłak; Piotr Smoleński
Journal:  Molecules       Date:  2020-02-08       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.